EMA — authorised 1 August 2000
- Application: EMEA/H/C/000308
- Marketing authorisation holder: Novo Nordisk A/S
- Local brand name: NovoMix
- Indication: Treatment of diabetes mellitus.
- Status: approved
🇪🇺 insulin aspart + insulin aspart protamin in European Union
EMA authorised insulin aspart + insulin aspart protamin on 1 August 2000
Marketing authorisation
Other Diabetes approved in European Union
Frequently asked questions
Is insulin aspart + insulin aspart protamin approved in European Union?
Yes. EMA authorised it on 1 August 2000.
Who is the marketing authorisation holder for insulin aspart + insulin aspart protamin in European Union?
Novo Nordisk A/S holds the EU marketing authorisation.